Oligonucleotide CDMO Services Brochure

Founded in 1998, Hongene is a global leader in nucleic acid therapeutics with 1,600+ employees, offering end‑to‑end oligonucleotide CDMO services from preclinical development to cGMP clinical supply and commercial manufacturing. Key differentiators: vertical integration (building blocks to drug product), world‑leading capacity (Shanghai Fengxian site opened 2025, Hungary site targeted 2028), global cGMP standards, supply chain control, customer partnership, and advanced technologies (proprietary HiPEL™ chemoenzymatic ligation platform offering higher yields, purity, scalability, and sustainability over conventional SPOS for long/complex constructs). Comprehensive quality, regulatory, and CMC support are provided, with the Fengxian site already audited by MNCs, Big Pharma, and regulators. Hongene is committed to making RNA medicines accessible and affordable.

(For an in‑depth comparison of HiPEL™ vs. SPOS performance data, capacity expansion roadmaps, and successful client case studies, please download the full service brochure.)